Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Status:
Withdrawn
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Heart failure (HF) is a disease that is caused by a reduced heart muscle function. Reduced
heart muscle function can occur as a consequence of reduced pumping activity from a weak
heart muscle or because of a stiff heart muscle. This study is looking at the effectiveness
of Natrecor (nesiritide) in patients that require hospitalization due to worsening heart
failure as a result of a stiff or thickened heart muscle. Natrecor is a man-made version of a
protein that my body makes on its own and has been approved for the treatment of patients
requiring hospital admission for heart failure and have shortness of breath at rest or with
minimal activity.
Natrecor has shown to lower the pressures in the heart and decreases the congestion in the
lungs. This study is being done to see if the addition of a Natrecor to standard medical
therapy for HF will improve symptoms faster or more completely than giving only the standard
treatment for CHF.
Phase:
Phase 4
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey